Salt Selection in Drug Development - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Salt Selection in Drug Development
The selection of an appropriate salt form for a potential drug candidate is an opportunity to modulate its characteristics to improve bioavailability, stability, manufacturability, and patient compliance.


Pharmaceutical Technology
Volume 3, Issue 32

Conclusion

Selecting an optimal salt form for development is a critical step in ensuring the efficient and successful development of a robust product. Salt selection requires a well designed screening strategy that fulfills the essential and desirable criteria that set the standard for salt screening. In addition, salt selection procedures must also assess the regulatory, intellectual, and marketing considerations to balance the drug's physicochemical and biopharmaceutical properties against commercial considerations.

Lokesh Kumar is a student, Aeshna Amin is a student, and Arvind K. Bansal* is an associate professor at the National Institute of Pharmaceutical Education and Research, Sector-67, Phase-X, S.A.S. Nagar, Punjab 160062, India, tel +91 0 172 2214682 87, fax +91 0 172 2214692,

*To whom all correspondence should be addressed.

Submitted: Apr. 2, 2007. Accepted: Apr. 5, 2007.

References

1. C.G. Wermuth and P.H. Stahl, "Introduction," in Handbook of Pharmaceutical Salts: Properties, Selection and Use, P.H. Stahl and C.G. Wermuth, Eds. (Wiley–VCH, Weinheim, Germany, 2002), pp. 1–7.

2. S.M. Berge, L.M. Bighley, and D.C. Monkhouse, "Pharmaceutical Salts," J. Pharm. Sci. 66 (1), 1–19 (1977).

3. Tessella Scientific Software Solutions, "Automated Salts and Polymorph Screening," http://www.tessella.com/Services/CaseStudies/pdfs/e_GSK_ASAP.pdf, accessed Dec. 15, 2006.

4. B.D. Anderson and R.A. Conradi, "Predictive Relationships in the Water Solubility of Salts of a Nonsteroidal Anti-inflammatory Drug," J. Pharm. Sci. 74 (8), 815–820 (1985).

5. S.N. Bhattachar, L.A. Deschenes, and J.A. Wesley, "Solubility: It's Not Just for Physical Chemists," Drug Discov. Today 11 (21/22), 1012–1018 (2006).

6. L.D. Bighley, S.M. Berge, and D.C. Monkhouse, "Salt Forms of Drugs and Absorption," in Encyclopedia of Pharmaceutical Technology, J. Swarbrick and J.C. Boylan, Eds. (Marcel Dekker, New York, 1996), pp. 453–499.

7. "Properties of the Solid State," in Physicochemical Principles of Pharmacy, A.T. Florence and D. Attwood, Eds. (Macmillan Press Ltd., London, 3rd ed., 1998), pp. 5–34.

8. P. L. Gould, "Salt Selection for Basic Drugs," Int. J. Pharm. 33 (1–3), 201–217 (1986).

9. P.H. Stahl and M. Nakano, "Pharmaceutical Aspects of the Drug Salt Form," in Handbook of Pharmaceutical Salts—Properties, Selection, and Use, P.H. Stahl and C.G. Wermuth, Eds. (Wiley–VCH, Weinheim, Germany, 2002), pp. 83–116.

10. M.K. Chourasia and S.K. Jain, "Pharmaceutical Approaches to Colon Targeted Drug Delivery Systems," J. Pharm. Pharm. Sci. 6 (1), 33–66 (2003).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
30%
Breakthrough designations
20%
Protecting the supply chain
50%
Expedited reviews of drug submissions
0%
More stakeholder involvement
0%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Source: Pharmaceutical Technology,
Click here